Context Patients with Prader-Willi syndrome (PWS) have an increased fat mass and decreased lean body mass. GH-treated young adults with PWS who have attained adult height benefit from continuation of growth hormone (GH) treatment, as GH maintained their improved body composition, whereas fat mass increased during the placebo period. Adults with PWS are predisposed to T2DM and cardiovascular disease. Whether GH affects metabolic health profile of this patient group is unknown. Objective To investigate the effects of GH vs placebo on metabolic health, in young adults with PWS who were GH-treated for many years during childhood and had attained adult height (AH). Method A 2-year, randomized, double-blind, placebo-controlled crossover study with stratification for gender and BMI in 27 young adults with PWS. Intervention with GH (0Á67 mg/m 2 / day) and placebo, both for 1-year duration. Results Compared to placebo, GH treatment resulted in similar glucose and insulin levels during oral glucose tolerance test. Only fasting glucose and insulin were slightly higher during GH vs placebo (+0Á2 mmol/l and +18Á4 pmol/l), although both remained within normal ranges in both phases. Blood pressure and lipid profile were similar after GH vs placebo. At baseline (AH) and during GH, no patients had metabolic syndrome, while 1 developed it during placebo treatment.
Introduction
Prader-Willi syndrome (PWS) is a neurogenetic disorder caused by the lack of expression of paternally expressed genes located on the PWS region of chromosome 15, 1,2 with clinical findings that change over age. Infancy is characterized by muscular hypotonia and failure to thrive, while obesity, hyperphagia, psychomotor delay and behavioural problems are prominent during childhood and adulthood. 3, 4 The body composition of patients with PWS is abnormal, with increased fat mass (FM) and decreased lean body mass (LBM), even if there is no obesity. 2, [4] [5] [6] [7] [8] In children with PWS, the benefits of growth hormone (GH) treatment are well-established without adverse effects on glucose parameters, lipid profile and blood pressure. 5 GH improves body composition, bone mineral density, psychomotor development, cognition, adaptive functioning, linear growth and adult height (AH) 5, [9] [10] [11] [12] and has substantially changed the phenotype of children with PWS. Currently, when young adults with PWS without GHD have attained AH, they have to discontinue GH treatment. We recently demonstrated an impressive increase in FM during the placebo period in GH-treated young adults with PWS who have attained AH, while continuation of GH maintains the improved body composition, indicating that they benefit from continuation of GH treatment. 13 Adults with PWS are predisposed to develop type 2 diabetes mellitus (T2DM) due to their abnormal body composition 14 and cardiovascular disease (CVD), because risk factors for CVD such as hypertension and hyperlipidaemia occur more often in PWS. 15 GH has diabetogenic effects, but there are no studies on the metabolic effects of GH vs placebo in young adults with PWS who were treated with GH during childhood and had attained AH. Studies in older PWS patients, who were GHuntreated at inclusion, found no major side effects of GH on metabolic health profile.
As there were no negative effects of GH on the metabolic health profile in GH-treated children and GH-untreated adults with PWS, we hypothesized that GH vs placebo would result in a similar or even more favourable metabolic profile after attainment of AH. We therefore investigated the effects of GH vs placebo on the metabolic health profile of young adults with PWS after attainment of AH, in a 2-year, randomized, double-blind crossover study.
Subjects and methods

Subjects
Inclusion criteria were (i) genetically confirmed diagnosis of PWS by a positive methylation test; (ii) GH treatment during childhood for at least 2 years and being on GH at time of inclusion; and (iii) AH attainment, defined as a height velocity <0Á5 cm per 6 months and a complete epiphyseal fusion. Exclusion criteria were (i) medication to reduce weight (fat) or (ii) noncooperative behaviour.
From June 2008 to January 2014, 33 young adults with PWS aged 14Á1-20Á2 years fulfilled the inclusion criteria, but two did not want to continue daily injections and three refused to participate due to too large a burden of hospital visits. Twentyeight subjects were included, but one 16Á7-year-old participant (BMI 25Á0 kg/m 2 ) died due to gastric rupture 3 months after the study start while receiving placebo. Her baseline characteristics were not significantly different from the other patients and were excluded from analysis. Growth hormone treatment was prescribed during childhood at an initial dose of 1 mg/m 2 /day, and the dose was lowered in eight children due to high serum IGF-I levels. In this study, the GH dose was 0Á67 mg/m 2 /day (%0Á023 mg/kg/day), which was considerably lower than during childhood. The most important other medications were sex steroid replacement therapy in 12 (42Á9%) young adults, thyroid hormone supplementation in 8 (28Á6%), modafinil in 2 (7Á1%) and risperidone and citalopram in 1 (3Á6%) adolescent; doses were not changed during the study. All patients were on strict diet and exercise programmes.
Design
A 2-year, randomized, double-blind, placebo-controlled, crossover study investigated the effects of 1-year placebo vs 1-year GH on metabolic health profile. Young adults were stratified according to gender and BMI (below/above 25 kg/m 2 ) and then randomly and blindly assigned to receive 1 year of subcutaneous injections once daily at bedtime of either 0Á67 mg/m 2 /day GH (Genotropin â , 5 mg/ml; Pfizer Inc, New York, NY, USA) or 1 year of identical appearing placebo (placebo, Pfizer), after which they crossed over to the alternative treatment for another year. According to the FDA, a washout period should be at least three times the half-life of a drug. 18 As the half-life of GH is only 2-3 h and the study duration per phase was 1 year, no washout period was implemented. An independent statistician generated the random allocation sequence. Investigators were blinded for the allocation. An independent physician monitored safety during the study. During the entire study period, unblinding was not necessary. Standing height was measured with a calibrated Harpenden stadiometer, weight was determined on a calibrated scale (ServoBalance KA-20-150S), and BMI was calculated. Height, weight and BMI were expressed as SDS, adjusted for age and sex. 20, 21 SDS values were calculated with GrowthAnalyser 4.0 (www. growthanalyser.org). Systolic blood pressure (BP) and diastolic blood pressure (BP) were measured using an appropriately sized cuff, while patients were in the sitting position. As height is an important determinant of BP, BP was expressed as standard deviation scores (SDS), adjusted for height and sex. 22 Fat mass percentage (FM) was measured by DXA. 13 
Measurements
Assays
Blood samples were collected after an overnight fast and measured in a single laboratory: glucose, insulin, IGF-I, IGFBP-3, TC, HDLc and TG. LDLc was calculated using the Friedewald formula: LDLc (mmol/l) = TC-HDLc-0Á45*TG. 23 Blood samples during the OGTT for glucose and insulin determination were obtained after 30, 60, 90 and 120 min after ingestion and immediately assayed. 24 Levels of IGF-I and IGFBP-3 were measured and expressed as SDS, adjusting for age and gender. 13, 25 Lipids were determined as described. 26 
Metabolic syndrome
Revised criteria of the National Cholesterol Education Program (NCEP; Adult Treatment Panel III) were used to determine components of the metabolic syndrome. 27 Metabolic syndrome was defined as having three or more of the following risk factors: (i) Abdominal obesity: waist circumference in men >102 cm, and in women >88 cm; (ii) TG above 1Á7 mmol/l; (iii) HDLc in men below 1Á03, in women below 1Á3 mmol/l; (iv) BP ≥130/≥85 mm Hg; (v) Fasting glucose above 5Á6 mmol/l.
Statistics
Statistical analysis was performed with SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). Calculation of sample size based on body composition indicated that 20 subjects would be sufficient for a power of >90% with a significance level of 0Á05. To account for attrition, eight more patients were added. As data were normally distributed, parametric tests were used and data expressed as mean [standard deviation (SD)]. Effects of GH vs placebo were calculated using linear mixed model analysis with the outcomes measured at the end of the two treatment periods as dependent variable and with an unstructured covariance matrix. Possible carry-over effects were analysed by adding the interaction between period and treatment, but not found. In addition to the 2-year results, we also presented systolic and diastolic BP SDS and lipid levels during the 4 years prior to attainment of adult height, as significant changes in the years prior to the study might influence the interpretation. Linear mixed model analysis was used.
Study approval
Written informed consent was obtained from the patients and their caregivers. The study protocol was approved by the Medical Ethics Committee of the Erasmus University Medical Center, Rotterdam, and registered at Dutch Trial Register (www.trial register.nl NTR1038).
Results
Baseline characteristics Table 1 shows the clinical characteristics of 27 young adults (eight boys, 19 girls) with PWS at adult height (AH). Their mean age was 17Á2 (1Á8) years and BMI +0Á9 (1Á3) SDS. Nine (33Á3%) patients had a deletion, 15 (55Á6%) an mUPD, 2 (7Á4%) an ICD and 1 (3Á7%) a translocation. During childhood, GH treatment was started at a mean age of 8Á5 (3Á5) years and continued for 8Á7 (3Á2) years until AH. Boys had a mean AH of 174Á1 (3Á0) cm, being À1Á4 (0Á4) SDS and girls reached 159Á9 (7Á3) cm, being À1Á7 (1Á1) SDS. Both treatment regimens had similar baseline characteristics.
Metabolic health profile
Carbohydrate metabolism. Fig. 1 and Table 2 show glucose and insulin levels during OGTT after long-term GH treatment during childhood, at baseline of this study at adult height (AH), after 1 year of GH and after 1 year of placebo. At baseline, none of the patients had a fasting glucose above 5Á6 mmol/l, while IGT, defined as a glucose between 7Á8 and 11Á1 mmol/l at 120 min after glucose load, was present in four patients and none had T2DM. Compared to placebo, GH treatment resulted in similar glucose and insulin levels at 30, 60, 90 and 120 min after glucose load (Fig. 1) . Only fasting glucose and insulin levels were higher after GH treatment vs placebo, although both remained within the normal ranges in both phases (glucose 4Á7 vs 4Á5 mmol/l, P = 0Á012, and insulin 65Á8 vs 47Á4 pmol/l, P = 0Á037, respectively) ( Table 2 ). All other carbohydrate parameters were similar after GH vs placebo. Mean glucose at 120 min after glucose intake was similar (GH vs placebo 6Á0 vs 6Á1 mmol/l, P = 0Á998). The 120-min AUCs for glucose and insulin during OGTT were not significantly different after both treatment phases (P = 0Á343 and P = 0Á457, respectively), and the insulin/ glucose ratios at 30 and 120 min were similar after GH and placebo. IGT was present in two patients after 1 year of GH and in two other patients after 1 year of placebo. None of the patients developed T2DM.
Blood pressure. Fig. 2a,b shows systolic BP and diastolic BP during the 2-year crossover study and the 4 years before. At baseline, mean systolic BP and diastolic BP were significantly higher than height-and sex-matched controls (0Á5 and 0Á7 SDS, P = 0Á016 and P < 0Á001, respectively) ( Table 2 ), but there were only two patients with a systolic BP above +2 SDS (both +2Á2 SDS).
Compared to placebo, GH treatment resulted in a similar systolic BP and diastolic BP (P = 0Á547 and P = 0Á779). Four young adults had a systolic BP above +2 SDS after 1 year of GH, while two of them and one other had an elevated systolic BP after 1 year of placebo. Two young adults had a diastolic BP above +2 SDS after both GH and placebo, and 1 only after 1 year of placebo.
Serum lipid levels. Fig. 2c shows fasting serum lipid levels during the 2-year crossover study and the 4 years before. At baseline, all mean lipid levels were within the normal range (Table 2) . Levels above the normal range of TC and LDLc were found in, respectively, two and one patients, while one patient had a HDLc below the normal range.
Compared to placebo, GH treatment resulted in similar levels of TC, LDLc, HDLc and TG (P > 0Á415). One young adult had a TC above the upper limit of 5Á5 mmol/l after 1 year of GH, while another had an elevated TC after 1 year of placebo. LDLc and TG were not elevated after 1 year of GH treatment, while after 1 year of placebo, one patient had an LDLc higher than the upper limit of 3Á8 mmol/l, and this and another patient had a TG level higher than 1Á6 mmol/l. HDLc was not below the lower limit of 0Á9 mmol/l in any patient.
Metabolic syndrome. Table 3 shows the different components of the metabolic syndrome (MS). At baseline (AH), none of the patients had MS according to the revised NCEP criteria. 27 After 1 year of GH treatment, 12 components of MS were present; four patients had central obesity, three low HDLc levels and five a high BP, while none had high TG levels or high fasting glucose. After 1 year of placebo, there were 17 components of MS; five had central obesity, one high TG levels, six low HDLc levels, four high BP and one a high fasting glucose.
Compared to placebo, GH treatment did not result in MS. During the 2 years of study, one girl (3Á7%) developed MS. She had no MS symptoms after 1 year of GH, but after the subsequent year with placebo three symptoms were present.
Discussion
To our knowledge, this is the first 2-year, randomized, double-blind, placebo-controlled study in young adults with PWS who were treated with GH during childhood until AH, which investigates the effects of GH vs placebo on metabolic health. Our findings demonstrate that glucose-stimulated glucose and insulin levels during OGTT were similar during GH treatment vs placebo. Compared to placebo, GH treatment did not affect other carbohydrate parameters such as AUC of glucose and insulin, and insulin/glucose ratios. Fasting glucose and insulin levels were slightly higher during GH vs placebo therapy, but remained within the normal ranges during both phases and none developed T2DM. The prevalence of IGT and MS was similar after GH treatment and placebo, and BP and lipid profiles were not significantly different after GH therapy vs placebo. This indicates that GH does not affect carbohydrate parameters compared with placebo, with the exception of a slightly higher fasting glucose and insulin, and that GH therapy vs placebo does not disturb components of metabolic health.
Compared to placebo, GH treatment did not affect glucosestimulated glucose and insulin levels, AUC for glucose and insulin, and insulin/glucose ratios. These results of the OGTT are reassuring and demonstrate that glucose and insulin homoeostasis reacts appropriately without developing glucose intolerance during GH therapy vs placebo. The minor increase in fasting insulin with minimal influences on glucose metabolism is a well-known and physiological phenomenon during GH treatment. 5, 28 Our finding that GH treatment has only minimal effects without being pathologic concur with the conclusion of H€ oybye et al. 16 that GH treatment did not elicit pronounced adverse effect on glucose and insulin homoeostasis in older previously GH-untreated adults with PWS. Lipid levels remained similar during GH vs placebo therapy, while studies in other patient groups such as GHD or obesity found beneficial effects of GH treatment on lipid profiles. 29, 30 Our findings might be the result of the already quite favourable lipid profile of patients with PWS and the fact that hypercholesterolaemia does not seem to be frequent, probably due to the smaller amount of visceral fat. 31 Findings in older adults with PWS who were GH-untreated at inclusion were in line with our 
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Fig. 1 Glucose and Insulin during oral glucose tolerance test (OGTT).
Mean glucose and insulin levels during OGTT after long-term GH treatment during childhood at baseline (AH) (black circles), after 1 year of GH treatment (grey circles) and after 1 year of placebo (white triangles) of 27 young adults with PWS. #GH vs placebo P-value <0Á05, ¤Baseline vs placebo P-value <0Á05, other not significantly different.
results, 28 although Sode-Carlsen et al. 17 reported a small reduction in LDLc only, during GH therapy compared to placebo. Their patients were, however, GH-untreated and heavier at baseline, while our patients had already received 8 years of GH treatment before they participated in the present study, and this might have influenced the findings. In our cohort of patients who were GH-treated during childhood for many years, none had MS at attainment of AH and none developed MS during GH therapy after AH, while one developed MS during placebo treatment. In obese adults with PWS, a prevalence of MS of 41Á4% was reported, while it was only 4Á7% in the nonobese PWS subjects. 32 The authors concluded that obesity plays a significant role in metabolic health. Elaborating on this, it might be that the role of body composition, and subsequently GH treatment, is even larger. Continuation of GH prevents deterioration of body composition 13 and thus favourably affects metabolic health.
Patients with PWS have a relatively high insulin sensitivity with high adiponectin levels, which are thought to be protective with regard to T2DM and CVD. 31, [33] [34] [35] Besides the favourable effects of GH on adiponectin, 34 continuation of GH treatment at AH prevents the deterioration of body composition in young adults with PWS. During placebo, FM rose dramatically with a relative increase of 21Á5% in only 1 year, while GH treatment maintained the improved body composition with less FM and more LBM. 13 Thus, when GH treatment stops, the natural course of increasing obesity in PWS is no longer counteracted. As LBM is the primary tissue of insulin-stimulated glucose uptake, disposal and storage, 36 and obesity and FM are associated with MS, T2DM and CVD, 37 it is likely that the deterioration of body composition due to discontinuation of GH will impair glucose and insulin homoeostasis over time. This suggests that discontinuation of GH at AH might result in a worse metabolic health profile in the long term in young adults with PWS, and that the benefits of GH far outweigh the minimal effects on glucose and insulin homoeostasis. The percentage of patients with an mUPD was higher than previously described, 38 but an mUPD is more commonly found nowadays, probably related to the increasing maternal age at conception in Western countries. It is not only a diagnosis of PWS which influences risk of metabolic disease but also other risk factors such as obesity, advanced age, positive family history and low LBM. By choosing a crossover design, interindividual risk factors were eliminated and this strong design allowed a smaller sample size, especially important as PWS is a rare disorder. Ongoing monitoring of young adults with PWS receiving GH treatment is highly recommended as they are at risk of developing T2DM and CVD, although our study demonstrated reassuring findings. Additional studies are needed to confirm this in the longer term, as our patients are still young and received only 1 year of GH treatment.
In conclusion, this crossover study demonstrates that 1 year of GH treatment has no adverse effects on glucose homoeostasis, with similar glucose-stimulated glucose and insulin levels during OGTT, AUC of glucose and insulin, and insulin/glucose ratios during GH treatment and placebo. Fasting glucose and insulin levels remained within the normal ranges and were only slightly higher during GH treatment vs placebo. Blood pressure and lipid profile remained similar in both phases. None of the patients developed MS during GH treatment, while one developed MS during placebo. Thus, GH-treated young adults with PWS who have attained AH benefit from continuation of GH treatment without safety concerns regarding their metabolic health profile. 
